Loading...

Harmony Biosciences Holdings, Inc.

HRMY•NASDAQ
Healthcare
Biotechnology
$37.52
$0.81(2.21%)

Harmony Biosciences Holdings, Inc. (HRMY) Company Profile & Overview

Explore Harmony Biosciences Holdings, Inc.’s business operations, leadership, sector classification, and key company facts including IPO date, industry, and contact details.

Harmony Biosciences Holdings, Inc. (HRMY) Company Profile & Overview

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is based in Plymouth Meeting, Pennsylvania.

SectorHealthcare
IndustryBiotechnology
CEOJeffrey M. Dayno

Contact Information

https://www.harmonybiosciences.com
484 539 9800
630 West Germantown Pike, Plymouth Meeting, PA, 19462

Company Facts

268 Employees
IPO DateAug 19, 2020
CountryUS
Actively Trading

Frequently Asked Questions

;